Results 171 to 180 of about 41,938 (307)

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma. [PDF]

Blood Adv
Iacoboni G, Kyvsgaard ER, Navarro Garcés V, Russler-Germain DA, Lewis K, Martín García-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela D, Ku M, Gómez P, Valencia E, Vega G, Jiménez-Ubieto A, Bastos-Oreiro M, Serna A, Husby S, De La Cruz B, Luan J, Camarillas S, Medina L, Cabero A, Córdoba R, Canales M, Sancho JM, Bosch F, Sureda A, Schuster S, Cheah CY, Hutchings M, Barba P, Abrisqueta P.   +32 more
europepmc   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, EarlyView.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. [PDF]

MAbs
Sims GP, Scaletta L, Andrews J, Sims DA, Strain M, Sigurdardottir A, Kuriakose T, England E, Rajasinghe L, Jiang F, Xiong X, Neal F, Vinall L, Newton P, Boger E, Kim C, Dahlbäck H, Prothon S, Leander J, Darrah E, Collins M, Douglas G, White N, Day K, Vousden KA, Huntington CE, Close D.   +26 more
europepmc   +1 more source

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies [PDF]

, 2017
Arber, Caroline, Bonifant, Challice Lee, Cooper, Laurence J. N., Gerken, Claudia, Gottschalk, Stephen, Iwahori, Kota, Kakarla, Sunitha, Rodriguez-Cruz, Tania, Song, Xiao-Tong, Szöőr, Árpád, Torres, David, Velasquez, Mireya Paulina   +11 more
core   +1 more source

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC. [PDF]

Biomark Res
Zhi X, Wang J, Guo J, Luo L, Sun H, Li Y, Zhao Z, Wang C, Zhu L, Li X, Wang F, Li F, Yu K, Ren S.   +13 more
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis. [PDF]

Antib Ther
Zhang Q, Song S.
europepmc   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source